RECOMBINANT HUMAN TUMOR NECROSIS FACTOR RECEPTOR Fc FUSION PROTEIN THERAPY IN KIDNEY TRANSPLANT RECIPIENTS UNDERGOING OKT3 INDUCTION THERAPY1,2
| Autor: | Christopher L. Marsh, Consuelo Blosch, John P. McVicar, Connie L. Davis, Rachael S. Griffin, Mark H. Wener, Erik J. Novak, James D. Perkins, Darlene Barr, Allen Farrand |
|---|---|
| Rok vydání: | 1998 |
| Předmět: |
Transplantation
Kidney medicine.medical_specialty Creatinine business.industry medicine.medical_treatment chemical and pharmacologic phenomena medicine.disease Gastroenterology chemistry.chemical_compound medicine.anatomical_structure Cytokine chemistry Internal medicine Immunopathology Chemoprophylaxis Immunology medicine Tumor necrosis factor alpha business Kidney disease |
| Zdroj: | Transplantation. 66:1732-1735 |
| ISSN: | 0041-1337 |
| Popis: | Background. Initial doses of OKT3 are associated with a cytokine-induced acute clinical syndrome (ACS). This study assessed the safety of a recombinant human tumor necrosis factor receptor fusion protein (TNFR:Fc) given to minimize OKT3-ACS symptoms in renal allograft recipients undergoing induction therapy. Methods. Sixteen patients were randomized into treatment or control groups. Treated patients received TNFR:Fc 1 hr before OKT3 on days 0 and 3. Patients were monitored after transplant for OKT3-ACS symptoms. Levels of cytokines, serum creatinine, and C-reactive protein were followed. Results. Patients receiving TNFR:Fc had lower OKT3-ACS symptoms as measured by a scoring system. There was a higher incidence of infection in treated patients (10/12) compared to controls (1/4) in the 3 months after transplant, but the etiology of this difference was unclear. There were no significant differences in cytokine profiles. Conclusions. TNFR:Fc is well tolerated by renal transplant patients receiving OKT3 induction therapy and modestly decreases the symptoms associated with OKT3-ACS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|